Writing
Author: Mario Peshev
Novo Nordisk Faces Major Stock Drop Amid Leadership Change and Weaker Sales Outlook
Discover why Novo Nordisk's stock dropped sharply and explore recovery strategies under new CEO Mike Doustdar. Is it time to invest?
CAA's Bold Move into AI: Investing in Moonvalley to Redefine Hollywood's Future
Discover how Moonvalley's AI technology is transforming filmmaking, enhancing creativity and efficiency while addressing ethical concerns in Hollywood.
The Future of Business Intelligence: Why Traditional BI Alone Isn't Enough
Discover how Decision Intelligence enhances Business Intelligence by integrating real-time data and predictive analytics for better decision-making.
U.S.-China Trade Dynamics: Implications for TMC The Metals Company and the Future of Mineral Sourcing
Discover how U.S.-China trade relations impact TMC The Metals Company's stock and future in seabed mining. Explore key insights and opportunities!
The Charisma Paradox: Why Leadership Success Requires More Than Just Charm
Discover why charisma can be a liability in leadership. Learn how to prioritize integrity and competence for sustainable success.
IFL Enterprise Surges in Q1 FY26: A Look at Financial Growth and Market Trends
Discover IFL Enterprise's impressive Q1 FY26 growth, challenges in agriculture, and the role of technology. Explore more!
Why Value Investing Thrives Abroad: Insights from Daniel Rasmussen
Discover why value investing thrives abroad compared to the U.S. Explore insights from Daniel Rasmussen on global market dynamics.
Tilray's Financial Woes: The High Cost of Overvaluation and What It Means for Investors
Discover the reasons behind Tilray's stock drop and what it means for investors in the cannabis market. Explore insights and strategies for recovery.
Kylian Mbappe Takes the Legendary Number 10 Jersey at Real Madrid: A New Era Begins
Explore the significance of the number 10 jersey at Real Madrid and how Mbappe's new role impacts the club's future and merchandise sales.
Why Bristol-Myers Squibb (BMY) is a Top Dividend Stock for Investors
Discover why Bristol-Myers Squibb (BMY) is a top dividend stock with a 5.12% yield and 16 years of growth. Explore its financial strength and market position!
The weekly briefing
Growth Shuttle Insider
A weekly email on how value is built in private equity and mid-market companies, written by someone who does the work. There is no fund or deal behind it.
- 29,000+ operators and investors
- Weekly in your inbox
- Free and always will be